Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy

A randomized prospective crossover trial

Zeynep Biyik, Yalcin Solak, Huseyin Atalay, Abduzhappar Gaipov, Figen Guney, Suleyman Turk

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: In dialysis patients, painful peripheral neuropathy (PPN) is associated with sleep disturbance and mood disorders. Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN. Methods: Fifty hemodialysis patients with PPN were randomized into 2 groups, to receive gabapentin and pregabalin, respectively. After 6 weeks of treatment, patients underwent a 2-week washout period, followed by crossover and another 6 weeks of treatment. All patients underwent electromyography (EMG) at the outset and completed the modified Short Form of McGill Pain Questionnaire (SF-MPQ), the Beck Depression Inventory (BDI) and the Pittsburgh Sleep Quality (PSQI) assessment at baseline and at the end of the study. Forty out of 50 patients completed the 14-week study period. Results: Thirty-one out of 40 patients (77.5 %) had EMG-proven PPN. Both gabapentin and pregabalin significantly improved SF-MPQ, BDI and PSQI scores at the end of the study compared with pretreatment scores (p < 0.001). There was no significant difference between the two drugs in any studied parameter. ConclusIons: Our results showed for the first time a good and similar efficacy of both drugs on pain intensity, quality of sleep and depression in hemodialysis patients with PPN.

Original languageEnglish (US)
Pages (from-to)831-837
Number of pages7
JournalInternational Urology and Nephrology
Volume45
Issue number3
DOIs
StatePublished - Jun 1 2013

Fingerprint

Peripheral Nervous System Diseases
Cross-Over Studies
Renal Dialysis
Sleep
Depression
Electromyography
Pain Measurement
Equipment and Supplies
gabapentin
Pregabalin
Mood Disorders
Pharmaceutical Preparations
Dialysis
Painful Neuropathy
Pain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy : A randomized prospective crossover trial. / Biyik, Zeynep; Solak, Yalcin; Atalay, Huseyin; Gaipov, Abduzhappar; Guney, Figen; Turk, Suleyman.

In: International Urology and Nephrology, Vol. 45, No. 3, 01.06.2013, p. 831-837.

Research output: Contribution to journalArticle

@article{271be513799f4b20aa10d1b0921ad283,
title = "Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: A randomized prospective crossover trial",
abstract = "Purpose: In dialysis patients, painful peripheral neuropathy (PPN) is associated with sleep disturbance and mood disorders. Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN. Methods: Fifty hemodialysis patients with PPN were randomized into 2 groups, to receive gabapentin and pregabalin, respectively. After 6 weeks of treatment, patients underwent a 2-week washout period, followed by crossover and another 6 weeks of treatment. All patients underwent electromyography (EMG) at the outset and completed the modified Short Form of McGill Pain Questionnaire (SF-MPQ), the Beck Depression Inventory (BDI) and the Pittsburgh Sleep Quality (PSQI) assessment at baseline and at the end of the study. Forty out of 50 patients completed the 14-week study period. Results: Thirty-one out of 40 patients (77.5 {\%}) had EMG-proven PPN. Both gabapentin and pregabalin significantly improved SF-MPQ, BDI and PSQI scores at the end of the study compared with pretreatment scores (p < 0.001). There was no significant difference between the two drugs in any studied parameter. ConclusIons: Our results showed for the first time a good and similar efficacy of both drugs on pain intensity, quality of sleep and depression in hemodialysis patients with PPN.",
author = "Zeynep Biyik and Yalcin Solak and Huseyin Atalay and Abduzhappar Gaipov and Figen Guney and Suleyman Turk",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s11255-012-0193-1",
language = "English (US)",
volume = "45",
pages = "831--837",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy

T2 - A randomized prospective crossover trial

AU - Biyik, Zeynep

AU - Solak, Yalcin

AU - Atalay, Huseyin

AU - Gaipov, Abduzhappar

AU - Guney, Figen

AU - Turk, Suleyman

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Purpose: In dialysis patients, painful peripheral neuropathy (PPN) is associated with sleep disturbance and mood disorders. Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN. Methods: Fifty hemodialysis patients with PPN were randomized into 2 groups, to receive gabapentin and pregabalin, respectively. After 6 weeks of treatment, patients underwent a 2-week washout period, followed by crossover and another 6 weeks of treatment. All patients underwent electromyography (EMG) at the outset and completed the modified Short Form of McGill Pain Questionnaire (SF-MPQ), the Beck Depression Inventory (BDI) and the Pittsburgh Sleep Quality (PSQI) assessment at baseline and at the end of the study. Forty out of 50 patients completed the 14-week study period. Results: Thirty-one out of 40 patients (77.5 %) had EMG-proven PPN. Both gabapentin and pregabalin significantly improved SF-MPQ, BDI and PSQI scores at the end of the study compared with pretreatment scores (p < 0.001). There was no significant difference between the two drugs in any studied parameter. ConclusIons: Our results showed for the first time a good and similar efficacy of both drugs on pain intensity, quality of sleep and depression in hemodialysis patients with PPN.

AB - Purpose: In dialysis patients, painful peripheral neuropathy (PPN) is associated with sleep disturbance and mood disorders. Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN. Methods: Fifty hemodialysis patients with PPN were randomized into 2 groups, to receive gabapentin and pregabalin, respectively. After 6 weeks of treatment, patients underwent a 2-week washout period, followed by crossover and another 6 weeks of treatment. All patients underwent electromyography (EMG) at the outset and completed the modified Short Form of McGill Pain Questionnaire (SF-MPQ), the Beck Depression Inventory (BDI) and the Pittsburgh Sleep Quality (PSQI) assessment at baseline and at the end of the study. Forty out of 50 patients completed the 14-week study period. Results: Thirty-one out of 40 patients (77.5 %) had EMG-proven PPN. Both gabapentin and pregabalin significantly improved SF-MPQ, BDI and PSQI scores at the end of the study compared with pretreatment scores (p < 0.001). There was no significant difference between the two drugs in any studied parameter. ConclusIons: Our results showed for the first time a good and similar efficacy of both drugs on pain intensity, quality of sleep and depression in hemodialysis patients with PPN.

UR - http://www.scopus.com/inward/record.url?scp=84879500053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879500053&partnerID=8YFLogxK

U2 - 10.1007/s11255-012-0193-1

DO - 10.1007/s11255-012-0193-1

M3 - Article

VL - 45

SP - 831

EP - 837

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 3

ER -